Friday, December 6, 2024
12/6/2024
DESCRIPTION (provided by applicant): B-cell dysfunction is a hallmark of HIV/SIV infection that begins very early in infection even before CD4 T cell depletion. Increasing evidence suggests that heightened B-cell activation, lack of memory B-cell restoration and impaired vaccine induced antibody responses persists even in patients receiving suppressive anti- retroviral therapy. Even though our understanding of B-cell dynamics in HIV/SIV infection has significantly improved, the molecular mechanisms underlying B-cell dysfunction remain poorly understood. In addition to cytokines and transcription factors, recent studies show miRNA-mediated gene regulation to be critical for B- cell differentiation, maturation, activation and autoimmune responses. Extensive studies in autoimmune diseases associated with B-cell defects have revealed a causative role for microRNAs in disease pathogenesis resulting in their identification as promising therapeutic targets. However, the role of miRNAs in HIV induced B-cell dysfunction is lacking. Our preliminary studies for this application identified significant dysregulation of miRNAs linked to B-cell activation and lymphomagenesis in purified B-cells from chronically SIV-infected macaques. Interestingly and more importantly, chronic THC treatment to SIV-infected macaques markedly inhibited their expression suggesting their immense therapeutic potential for attenuating immune (B-cell) activation and slowing disease progression. Based on our strong preliminary data demonstrating that miRNA expression is dysregulated in B-cells in HIV/SIV infection, we hypothesize that this leads to B-cell dysfunction which contributes to immune activation and HIV disease progression. Further, we hypothesize that chronic 9- THC treatment may reduce inflammation, restore immune (B-cell) function, and slow HIV/SIV disease progression by modulating miRNA expression. A major goal of this application is to identify miRNA mechanisms associated with B-cell dysfunction and cannabinoid mediated suppression of B-cell activation. The project has three specific aims: 1) Test the hypothesis that miR-34a and miR-155 targeting of SIRT1 leads to enhanced acetylated-p65 and acetylated-FOXO3a expression, causing B-cell hyperactivity and apoptosis, respectively. 2) Identify miRNA mechanisms of cannabinoid induced suppression of B-cell activation in blood, lymph nodes, and intestine at three different time points following SIV infection. 3) Determine the effect of combination anti-retroviral treatment (cART) in conjunction with chronic 9-THC administration on inflammation, chronic immune activation, viral replication, miRNA expression, SIRT1 levels, B-cell activation and apoptosis. The proposed research is novel and applies state of the art immunological and molecular approaches to address a significant gap in our understanding of the post-transcriptional mechanisms underlying B-cell dysfunction. Additionally and more importantly, the results will deepen our understanding of the mechanisms underlying the anti-inflammatory effects of cannabinoids and have important therapeutic implications for targeted immune modulation in HIV and other autoimmune diseases with B-cell defects.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
